V. King

发表

A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis

J. Tena, M. Stegemann, J. Wren, 2013, Veterinary dermatology.

Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis

L. Caneva, G. Sture, M. Visser, 2021, BMC Veterinary Research.

Vaccination of dogs with Duramune DAPPi+LC protects against pathogenic canine parvovirus type 2c challenge

J. Salt, S. Wilson, C. Stirling, 2013, Veterinary Record.

A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines

M. Balasch, M. Bandrick, L. Taylor, 2022, Veterinary Research.

Efficacy of a Parapoxvirus ovis-based immunomodulator against equine herpesvirus type 1 and Streptococcus equi equi infections in horses.

J. Salt, R. Kenna, A. Cullinane, 2014, Veterinary microbiology.

Use of an anti-GnRF vaccine to suppress estrus in crossbred Iberian female pigs.

M. Gispert, A. Velarde, E. Fàbrega, 2015, Theriogenology.

Comparison of effectiveness of cefovecin, doxycycline, and amoxicillin for the treatment of experimentally induced early Lyme borreliosis in dogs

J. Hardham, B. Wagner, R. Marconi, 2015, BMC Veterinary Research.

Comparative efficacy of a new spot-on combination product containing selamectin and sarolaner (Stronghold®Plus) versus fluralaner (Bravecto®) against induced infestations with Ixodes ricinus ticks on cats

T. Geurden, J. Liebenberg, J. Fourie, 2017, Parasites & Vectors.

Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.

A. Gonzales, T. Fleck, S. Lesman, 2022, Journal of veterinary pharmacology and therapeutics.

Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge.

K. Stuke, A. Thomas, K. Southwick, 2014, Vaccine.